RESUMEN
Hepatitis E has emerged as a major transfusion-transmitted infectious risk. Two recipients of plasma from 2 lots (A and B) of pooled solvent/detergent-treated plasma were found to be infected by hepatitis E virus (HEV) that was determined to have been transmitted by the solvent/detergent-treated plasma. HEV RNA viral loads were 433 IU in lot A and 55 IU in lot B. Retrospective studies found that 100% (13/13) of evaluable lot A recipients versus 18% (3/17) of evaluable lot B recipients had been infected by HEV (p<0.001), albeit not necessarily at time of transfusion. Among evaluable recipients, 86% with a transfused HEV RNA load >50,000 IU were infected, most likely by the HEV-containing solvent/detergent-treated plasma, versus only 7% with a transfused HEV RNA load <50,000 IU (p<0.001). Overall, solvent/detergent-treated plasma might harbor HEV. Such an occurrence might result in a dose-dependent risk for transfusion-transmitted hepatitis E.
Asunto(s)
Donantes de Sangre , Virus de la Hepatitis E , Hepatitis E , Plasma , Detergentes , Hepatitis E/epidemiología , Hepatitis E/transmisión , Virus de la Hepatitis E/genética , Humanos , ARN Viral , Estudios Retrospectivos , SolventesRESUMEN
BACKGROUND: In France, the risk of HIV transmission by transfusion was reduced by implementing pooled nucleic acid testing (NAT) in 2001 and individual NAT in 2010. We report here the first case in France of transfusion of human immunodeficiency virus (HIV)-infected blood donated during HIV pre-ramp-up phase that tested individual NAT negative. METHODS: Blood donations are screened for HIV antibodies and HIV RNA (ProcleixUltrio, Grifols; limit of detection at 95%, 23 copies/mL). When a repeat donor tests positive for HIV, a repository sample from the previous donation is tested with the Cobas Taqman HIV-1 test (CTM, Roche; limit of detection at 95%, 17 copies/mL). RESULTS: In August 2017, a 57-year-old male repeat donor was screened positive for HIV antibodies and RNA (plasma viral load, 11,599 copies/mL). The previous donation had tested negative with Ultrio in March 2017 but was positive with an unquantifiable plasma viral load when tested with CTM. Sequencing showed no mismatch between Ultrio primers/probes and the target sequence. HIV transmission was excluded by lookback studies in the recipient of platelets, which had been pathogen reduced, but not in the recipient of RBCs due to premature death. CONCLUSION: This case demonstrates that the risk of contaminated donations due to the early HIV infection phase going undetected by highly sensitive NAT is real but exceptional. The absence of transmission to the platelets recipient could be due to the very low viral inoculum and/or to the efficacy of the viral inactivation. This case also highlights the additional value of a systematic donation archiving and the importance of donor education and predonation selection.
Asunto(s)
Donantes de Sangre , Transfusión Sanguínea , Infecciones por VIH/diagnóstico , Infecciones por VIH/transmisión , Técnicas de Amplificación de Ácido Nucleico , ADN Viral/análisis , ADN Viral/sangre , Anticuerpos Anti-VIH/sangre , Infecciones por VIH/sangre , VIH-1/genética , VIH-1/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Pruebas Serológicas , Carga Viral/genéticaRESUMEN
With the use of sensitive new technology, hyperacute graft rejection is currently reported as an extremely rare event due to prospective lymphocyte crossmatches and/or virtual crossmatches. In this case study we describe a case of fatal early graft failure after a cardiac transplant in a male recipient who had no anti-HLA antibodies detected before transplantation, but who received, during heart transplant surgery, a red blood cell concentrate containing high levels of graft-specific alloantibodies. In addition, we analyze the relationship between these alloantibodies and the occurrence of hyperacute allograft rejection.